Centessa Pharmaceuticals plc (ADR)
General ticker "CNTA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.2B (TTM average)
Centessa Pharmaceuticals plc (ADR) follows the US Stock Market performance with the rate: 52.2%.
Estimated limits based on current volatility of 1.9%: low 28.16$, high 29.24$
Factors to consider:
- Total employees count: 76 (-8.4%) as of 2023
- Top business risk factors: Labor/talent shortage/retention, Operational and conduct risks, Regulatory and compliance, Supply chain disruptions, Economic downturns and volatility
- Current price 36.5% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.79$, 21.66$]
- 2025-12-31 to 2026-12-31 estimated range: [7.14$, 16.53$]
Financial Metrics affecting the CNTA estimates:
- Negative: with PPE of -11.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -7.30 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 1.61 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
Short-term CNTA quotes
Long-term CNTA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $6.85MM | $0.00MM |
| Operating Expenses | $212.26MM | $178.14MM | $201.06MM |
| Operating Income | $-212.26MM | $-171.28MM | $-201.06MM |
| Non-Operating Income | $-4.69MM | $-4.86MM | $-31.86MM |
| Interest Expense | $7.28MM | $9.91MM | $10.09MM |
| R&D Expense | $155.08MM | $124.41MM | $150.24MM |
| Income(Loss) | $-216.95MM | $-176.14MM | $-232.91MM |
| Taxes | $-0.75MM | $-25.06MM | $2.84MM |
| Profit(Loss)* | $-216.21MM | $-151.09MM | $-235.76MM |
| Stockholders Equity | $336.17MM | $236.24MM | $401.55MM |
| Assets | $444.31MM | $360.25MM | $576.80MM |
| Operating Cash Flow | $-200.55MM | $-160.34MM | $-142.06MM |
| Capital expenditure | $1.14MM | $0.17MM | $0.03MM |
| Investing Cash Flow | $-0.93MM | $-127.00MM | $31.27MM |
| Financing Cash Flow | $0.46MM | $21.12MM | $364.75MM |
| Earnings Per Share** | $-2.31 | $-1.57 | $-2.06 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.